aTyr Pharma Inc (NASDAQ:LIFE)
| 4.27 Delayed Data As of Sep 18 |  +0.05 / +1.18%Today’s Change | 2.13 Today|||52-Week Range 7.62 | +2.40% Year-to-Date |
Latest LIFE News | Press Releases
| Dosing in Phase 1 trial in aTyr Pharma's ATYR1923 conducted in Japan Sep 15 / Seeking Alpha - Paid Partner Content | Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update Sep 11 / Seeking Alpha - Paid Partner Content |
| aTyr pharma announces $20M common stock purchase agreement Sep 14 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 4.22 |
| Today’s open | 4.26 |
| Day’s range | 4.22 - 4.34 |
| Volume | 1,823 |
| Average volume (3 months) | 110,328 |
| Market cap | $43.0M |
Data as of 3:59pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | +56.39% |
| Earnings growth (this year) | +69.94% |
| Earnings growth (next 5 years) | +13.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 33.16 |
| Price/Book | 0.80 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ONCTOncternal Therapeuti... | -0.00 | -0.23% |
| FWPForward Pharma A/S | 0.00 | 0.00% |
| PULMPulmatrix Inc | +0.04 | +3.63% |
| PRPHProphase Labs Inc | +0.77 | +25.67% |
Data as of 6:17pm ET, 09/18/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$0.74 |
| Annual revenue (last year) | $422.0K |
| Annual profit (last year) | -$23.6M |
| Net profit margin | -5,593.13% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
